Navigation Links
Acceleron awarded $1.5 million grant from Muscular Dystrophy Association to support ACE-031
Date:1/6/2011

Cambridge, Mass. Jan. 6, 2011 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it has been awarded a $1.5 million grant from the Muscular Dystrophy Association to support clinical studies of ACE-031 in Duchenne Muscular Dystrophy (DMD), a disabling neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic designed to build muscle and increase strength by blocking proteins that inhibit muscle growth and strength.

"We are honored to be recognized and supported by the Muscular Dystrophy Association as we work collectively to develop promising therapies for the treatment of patients with Duchenne Muscular Dystrophy," said John Knopf, PhD, CEO of Acceleron. "This award along with our collaboration with Shire brings together the resources of several committed groups to evaluate the therapeutic potential of ACE-031 in DMD."

"Having invested more than $164 million on DMD-related research, MDA is eager to help Acceleron advance the clinical trial work needed to determine optimal doses of ACE-031 in terms of safety and pharmacodynamic activity," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors.

The MDA grant, awarded through the Association's Venture Philanthropy Program (MVP), will support ongoing clinical studies of ACE-031 in boys with DMD. The new investment will enable Acceleron to gather safe dosing and pharmcodynamic activity information vital to future studies of ACE-031. For more information on these ongoing studies, visit clinicaltrials.gov and query study identifiers NCT01099761 and NCT01239758.

"MDA is pleased to support Acceleron's efforts in the fight against Duchenne Muscular Dystrophy," said Valerie Cwik, M.D., MDA Executive Vice President Research and Medical Director. "Our strategic investment should help Acceleron expedite the next phase of ACE-031 human clinical trials."


'/>"/>

Contact: Jim Brown
jbrown@mdausa.org
520-529-5317
Muscular Dystrophy Association
Source:Eurekalert

Related biology news :

1. Stevens awarded $1M for advanced biofuels research
2. L-1 Identity Solutions Awarded New Massachusetts RMV Drivers License Contract Valued at an Estimated $32 Million
3. BIO-keys(R) Law Enforcement Group Awarded $700,000 in New Contracts
4. Broad Institute awarded major grant to bolster epigenomics research
5. LSUHSC awarded patent for compound inhibiting cancer and other diseases
6. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
7. Field-hospital-on-a-chip project awarded to nanoengineer from UC San Diego
8. SAIC Awarded $37 Million Contract to Support U.S. Army Program Executive Office - Enterprise Information Systems
9. Eastman Dental Center awarded $1.6 million to find ways to prevent cavities
10. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
11. BIO-key(R) Awarded PocketCop(R) Contracts From Major Law Enforcement Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology: